# LYSMD1

## Overview
The LYSMD1 gene encodes the protein LysM domain containing 1, which is characterized by the presence of a LysM domain, a motif known for its role in binding peptidoglycans and chitin. This protein is implicated in various cellular processes, including those related to genomic stability and immune response modulation. LYSMD1 has been studied in the context of cancer, particularly lung squamous cell carcinoma (LUSC) and breast cancer, where its expression levels are associated with genomic instability and tumor progression. The gene's involvement in microsatellite instability and its correlation with mismatch repair proteins suggest a role in DNA replication and repair mechanisms. Additionally, LYSMD1's potential impact on the tumor microenvironment and immune response highlights its significance in cancer prognosis and therapy (Hu2023Microsatellite; RajKumar2024Proteogenomic).

## Function


## Clinical Significance
The LYSMD1 gene has been implicated in lung squamous cell carcinoma (LUSC), where its expression is associated with genomic instability and poor clinical outcomes. High LYSMD1 expression is linked to increased microsatellite instability (MSI), TP53 mutations, and chromosomal alterations such as 3p loss and 3q amplification in LUSC samples. These genetic changes contribute to a high mutation rate and deficiencies in the DNA damage repair system, which are characteristic of LUSC (Hu2023Microsatellite). 

LYSMD1 is part of a microsatellite instability-related prognostic risk score (MSI-pRS), which helps predict outcomes in LUSC patients. The gene is positively correlated with mismatch repair (MMR) proteins, indicating its involvement in active DNA replication and transcription. However, LYSMD1 is negatively correlated with anti-cancer immunity, suggesting it may contribute to a cold tumor microenvironment and immunosuppression, potentially affecting the efficacy of immune checkpoint inhibitors (Hu2023Microsatellite).

In the context of difficult-to-treat breast cancer, LYSMD1 is associated with the 1q21 amplification, a common feature across all subtypes of this cancer, although specific clinical implications in breast cancer remain under investigation (RajKumar2024Proteogenomic).


## References


[1. (Hu2023Microsatellite) Zixin Hu, Zhening Liu, Jiabin Zheng, Yanmei Peng, Xingyu Lu, Jia Li, Kexin Tan, and Huijuan Cui. Microsatellite instability-related prognostic risk score (msi-prs) defines a subset of lung squamous cell carcinoma (lusc) patients with genomic instability and poor clinical outcome. Frontiers in Genetics, February 2023. URL: http://dx.doi.org/10.3389/fgene.2023.1061002, doi:10.3389/fgene.2023.1061002. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2023.1061002)

[2. (RajKumar2024Proteogenomic) Praveen-Kumar Raj-Kumar, Xiaoying Lin, Tao Liu, Lori A. Sturtz, Marina A. Gritsenko, Vladislav A. Petyuk, Tyler J. Sagendorf, Brenda Deyarmin, Jianfang Liu, Anupama Praveen-Kumar, Guisong Wang, Jason E. McDermott, Anil K. Shukla, Ronald J. Moore, Matthew E. Monroe, Bobbie-Jo M. Webb-Robertson, Jeffrey A. Hooke, Leigh Fantacone-Campbell, Brad Mostoller, Leonid Kvecher, Jennifer Kane, Jennifer Melley, Stella Somiari, Patrick Soon-Shiong, Richard D. Smith, Richard J. Mural, Karin D. Rodland, Craig D. Shriver, Albert J. Kovatich, and Hai Hu. Proteogenomic characterization of difficult-to-treat breast cancer with tumor cells enriched through laser microdissection. Breast Cancer Research, May 2024. URL: http://dx.doi.org/10.1186/s13058-024-01835-4, doi:10.1186/s13058-024-01835-4. This article has 0 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1186/s13058-024-01835-4)